Harm Reduction Approaches to Reducing Tobacco-Related Mortality

Abstract

Key Words reduced risk, reduced exposure products, harm reduction s Abstract Tobacco harm reduction approaches are gaining increased attention.Much of this attention is due to a growing concern that significant populations of smokers either do not want to quit or believe they are unable to quit smoking, and to a concern over tobacco-industry attempts to produce tobacco products that claim to result in less toxin exposure. Decreasing tobacco toxin exposure as a method for reducing mortality and morbidity may be a reasonable tobacco control strategy. However, the impact of this strategy must be explored both on individual and population levels. A significant amount of independent research is needed to inform policy decisions. Regulatory authority over potential reduced exposure products is also essential.

Calorie restriction increases cigarette use in adult smokers

“…The significant effect of both low-calorie diets on expired breath CO supports the validity of these findings. Expired breath CO, as a biomarker of actual smoke intake, is generally considered a more meaningful measure of smoking with respect to nicotine intake and tobacco dependence severity than is the behavioral measure of number of cigarettes smoked (Hatsukami et al 2004;Stratton et al 2001). The low-CHO/normal-calorie diet (also ketogenic) had no effect on either variable.…”

“…Smoking was assessed using two commonly used measures: number of cigarettes smoked, a behavioral measure, and expired breath carbon monoxide (CO) level (a biological measure of actual smoke intake that is considered to reflect nicotine intake and is associated with tobacco dependence severity; Hatsukami et al 2004;Stratton et al 2001). Subjects kept a half-hourly log of all cigarettes smoked, measured to the nearest eighth of a cigarette with the help of a cigarette diagram.…”

Medication screening for smoking cessation: a proposal for new methodologies

“…Limitations to these approaches with regard to predicting clinical trial efficacy outcomes will be emphasized, and suggestions will be made for developing methods that can improve this important area of research. Evaluation of medications aimed solely at harm reduction (i.e., reducing but not necessarily quitting smoking; Hatsukami et al 2004) or relief of temporary withdrawal and not abstinence per se will not be addressed.…”

Concepts liés à la réduction des méfaits dans la lutte au tabagisme

“…Hatsukami et coll. (2004) ont étudié les stratégies permettant de mesurer un changement dans l'exposition aux émissions toxiques (Hatsukami, Henningfield et Kotlyar, 2004). Bien que certaines méthodes (p. ex.…”